Sunesis Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 15   

Articles published

SNSS 6.19 +0.34 (5.81%)
price chart
Sunesis Pharmaceuticals Announces European Medicines Agency Acceptance ...
SOUTH SAN FRANCISCO, Calif., July 9, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Pediatric Committee of the European Medicines Agency (EMA) has issued a positive opinion on the Company's ...
Related articles »  
Melting Stocks- The Goodyear Tire & Rubber Company (GT), Sunesis ...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) released the presentation of updated results from an ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of Qinprezo(TM) (vosaroxin) in combination with decitabine in older ...
Related articles »  
Sunesis' Pediatric Plan Accepted in the EU - Analyst Blog
Late last week, Sunesis Pharmaceuticals, Inc. ( SNSS ) announced that the Pediatric Committee of the European Medicines Agency (EMA) accepted Sunesis' Pediatric Investigation Plan (PIP) for Qinprezo (vosaroxin) for first relapsed or refractory acute ...
Related articles »  
News Review - Prana Biotechnology Limited (ADR) (PRAN),Supernus ...
Sunesis Pharmaceuticals, Inc.(NASDAQ:SNSS)released the presentation of updated results from an ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of Qinprezo(TM) (vosaroxin) in combination with decitabine in older ...
Sunesis Pharmaceuticals, Inc. - Product Pipeline Review - 2014: New Research ...
This report provides comprehensive information on the current therapeutic developmental pipeline of Sunesis Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA ...
Biotech Overbought Stocks: Idenix Pharmaceuticals Inc (NASDAQ:IDIX ...
On 2 JUNE Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced the presentation of updated results from an ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of Qinprezo� (vosaroxin) in combination with ...
Today's Stocks � International Business Machines (NYSE:IBM), Apple Inc ...
On July 14, Late last week, Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced that the Pediatric Committee of the European Medicines Agency (EMA.
Better Buy: Clovis Oncology vs. Sunesis Pharmaceuticals
Oncology has long been one of the most active areas in pharmaceutical research, because new drugs tend to have high profit margins and long shelf lives and are often amenable to broad label expansions for a diversity of cancer types.
Related articles »